Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Long-Term Investments: 2020-2023

Historic Long-Term Investments for Editas Medicine (EDIT) over the last 4 years, with Dec 2023 value amounting to $104.0 million.

  • Editas Medicine's Long-Term Investments fell 18.50% to $39.2 million in Q2 2024 from the same period last year, while for Jun 2024 it was $39.2 million, marking a year-over-year decrease of 18.50%. This contributed to the annual value of $104.0 million for FY2023, which is 11.74% up from last year.
  • Latest data reveals that Editas Medicine reported Long-Term Investments of $104.0 million as of FY2023, which was up 11.74% from $93.1 million recorded in FY2022.
  • Editas Medicine's Long-Term Investments' 5-year high stood at $120.1 million during FY2021, with a 5-year trough of $93.1 million in FY2022.
  • For the 3-year period, Editas Medicine's Long-Term Investments averaged around $105.7 million, with its median value being $104.0 million (2023).
  • In the last 5 years, Editas Medicine's Long-Term Investments fell by 22.47% in 2022 and then climbed by 11.74% in 2023.
  • Over the past 4 years, Editas Medicine's Long-Term Investments (Yearly) stood at $109.7 million in 2020, then grew by 9.49% to $120.1 million in 2021, then declined by 22.47% to $93.1 million in 2022, then increased by 11.74% to $104.0 million in 2023.